Transplantation Immunology Flashcards

1
Q

process in which an individual receives cells or tissue from a second individual

A

transplantation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

a life saving procedure for end stage organ failure, malignancies, autoimmune diseases, immunodeficiency disorders and other

A

transplantation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

classified according to genetic disparity between the donor and the recipient (MHC)

A

transplants (grafts)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

tissue form one area to another from the same individual

A

autograft

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

tissue from identical twins

A

syngeneic graft/ syngraft/ isograft

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

tissue from different individuals in the same species

A

allograft

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

tissue from different species

A

xenograft

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

treatment of hyperacute allograft rejection

A

graft removal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q
  • occurs within mins to hrs after vascular supply
  • preformed anti-HLA Abs
  • antibody mediated
  • recipeint has been previously exposed to donor MHC Ags
A

hyperacute allograft rejection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q
  • weeks after engraftment
  • caused by CD4 and CD8 t cell activation
A

acute allograft rejection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

severity in acute allograft rejection is dependent on?

A

number of T cell clones activated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q
  • weeks, months, or years post transplantation
  • delayed type of hypersensitivity
A

chronic allograft rejection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

treatment of chronic allograft rejection

A

graft removal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

attack the tissues of immunocompromised recipient

A

T lymphocytes of immunocompetent donor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

cannot attack the graft with the same magnitude

A

immune system of the recipient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

targets T cells and are at risk of infection, malignancy and drug associated toxicity

A

patients under immunosuppressive therapies

17
Q

examples of immunosuppressive therapies?

A

corticosteroids, antimetabolic agents, calcineurin inhibitors, monoclonal antibodies

18
Q

types of histocompatibility screening

A

serologic typing, cellular typing and molecular typing

19
Q

are screened to ensure best possible genetic match of MHC to minimize the likelihood of rejection

A

recipients and potential donors

20
Q

determination of compatibility by the differences in MHC

A

tissue cross-matching

21
Q

method of choice until development of molecular approaches

A

serologic typing

22
Q

donor and recipient tissues are tested separately with Abs for various MHC antigens and the reaction is compared

A

serologic typing

23
Q

disadvantage of serologic typing

A

allelic differences cam only be detected if an Ab is available for the allele

24
Q

in vitro test used to mimic in vivo conditions of transplantation

A

mixed lymphocyte reaction

25
Q

why are the donor cells and recipient cells incubated for several days?

A

to allow T cells to be activated and proliferate in response to disparate MHC antigens

26
Q

is Limited to living donors only

A

mixed lymphocyte reaction

27
Q
  • DNA is cleaved by enzymes to obtain pattern of fragmentation
  • Degree of disparity is assessed by comparing patterns of fragmentation
A

RFLP analysis

28
Q
  • Direct amplification of a particular DNA sequence selected by the use of primers that isolates the gene of interest
  • Degree of disparity is assessed by comparing the selected sequences
  • May not be able to predict severity of rejection
  • Do not have the time constraint of MLR and is superior to serological approaches
A

PCR